ClinicalTrials.gg
RecruitingNCT06719206RedSedCanUpdated Oct 1, 2026

Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study

An interventional study of Digital self-management program in Breast Cancer, Colorectal Cancer (CRC) and Prostate Cancer, sponsored by Mälardalen University. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Mälardalen University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Oct 1, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Summary

Reducing sedentary behavior during treatment is important to reduce the risk of future health problems in individuals undergoing cancer treatment. Therefore, the goal of this project is with a multicenter randomised controlled design investigate whether a digital support intervention during ongoing neo- or adjuvant cancer treatment for breast, prostate or colon cancer is effective in reducing sedentary lifestyle and improving well-being in the short and long term.

Read the detailed description

Description of the project

This project is about investigating the effect of a digital support intervention to reduce sedentary behavior in people with breast, prostate, or colorectal cancer during neo- or adjuvant cancer treatment. The digital support intervention has been developed with patients and researchers and consists of existing high-quality technology that provides support for setting and following goals. The people who use the digital support intervention also receive support from a physiotherapist to set goals for reduced sedentary time and get to choose which activities will replace the time spent sedentary.

The goal of the project

The goal of the project is to investigate the effects of a digital support intervention on reduced sedentary and well-being during ongoing cancer treatment, both in the short and long term. In addition, the project will study the health-economic effects, and climate benefits of using the digital support intervention. By focusing on reducing a sedentary lifestyle and replacing it with daily activities and/or physical activity, the health of individuals is expected to be positively affected in the short term through, for example, increased well-being and reduced side effects from cancer treatment, and the long term through a reduced risk of developing complications and new illness related to the cancer treatment, such as cardiovascular disease.

02

Conditions studied

  • Breast Cancer
  • Colorectal Cancer (CRC)
  • Prostate Cancer
  • Neoadjuvant Therapy
  • Adjuvant Therapy

Keywords

  • sedentary behavior
  • behavior change
  • intervention
  • Randomized controlled trial
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's planned enrollment of 210 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Mälardalen University is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals diagnosed with breast, prostate, or colorectal cancer planned for or resently started neo- or treatment (e.g. chemotherapy, radiotherapy, endocrine treatment) at the hospitals in Uppsala and Västerås, Sweden.

Exclusion criteria

Exclusion Criteria:

  • Individuals diagnosed with dementia.
  • Individuals diagnosed with severe psychiatric disease.
  • Individuals with severe loss of vision, or communicative ability.
  • Individuals who cannot walk independently indoors with or without a walking aid.
  • Individuals completed treatment for other cancer diseases less than 12 months ago or not recovered from previous cancer treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants receive a digital support intervention

    Behavioral: Digital self-management program

  • No intervention
    Control

    Control condition. Individuals receive the care as usual provided by the healthcare only.

Interventions

  • BehavioralDigital self-management program

    The program consists of commercially available technologies, e.g. applications including behavour change techniques for reducing sedentary behavior (SB) (i.e. self-monitorization of physical activity, reminders for breaking SB/doing physical activity, and providing feedback on physical activity/breaks from SB) and a webpage containing information and tips (provided in short videos and text) regarding how to reduce SB. The participants will be receive help with setting goals for reducing time spent in sedentary/being active and help with planning for what activities to do to replace time in sedentary. Participants will then have access to the webpage and download the application to their smartphones. Follow-up meetings with the physiotherapist (digital or physical) will be conducted after 2, 8 and 12 weeks after start of intervention.

06

What researchers measure

Primary outcomes

  1. Sedentary behavior time

    The Axivity accelerometer is used for measuring the primary outcome of sedentary time, i.e. mean time spent in sedentary behavior/day.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.

Secondary outcomes

  1. Sedentary behavior bouts

    The Axivity accelerometer is used for measuring sedentary bouts, i.e. mean number of bouts/day and mean bouts time/day.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.

  2. Physical activity

    The Axivity accelerometer is used for measuring physical activity mean time/day and mean time spent in low-, moderate and high intensity physical activity.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months. Axivity is worn for 7 consecutive days at each measurement point.

  3. Health-related quality of life

    Patient reported health related quality of life will be assessed with European Organization for Research and Treatment of Cancer QLQ C 30 and diagnose specific modules BR23, PR26 and CR29.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.

  4. Health-related quality of life

    Patient reported health related quality of life will be assessed with EQ5D, and used for calculation of Quality Adjusted Life Years.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.

  5. Cancer related fatigue

    Patient reported outcome cancer related fatigue is measured with Brief Fatigue Inventory.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.

  6. Fear of movement

    Patient reported outcome Fear of movement is assessed with Cancer specific Tampa Scale for Kinesiophobia.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.

  7. Changes in health

    Patient reported outcome Changes in health is assessed with Patient Global Impression of Change Scale.

    Time frame: At 3-months, 6 months, 12 months and 24 months.

  8. Work ability

    Selected and adapted questions from Work Ability Index are used for assessing patient reported outcome work ability.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.

  9. Self-efficacy for reducing sedentary behavior

    Study specific question is used for assessing patient reported outcome of Self-efficacy for reducing sedentary behavior.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.

  10. Perceived support from peers

    Study specific question is used for assessing patient reported outcome of Perceived support from peers.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.

Other outcomes

  1. Demographic variables

    Study specific questions

    Time frame: Baseline

  2. Diagnoses

    Data regarding cancer diagnose and if any, co-morbid conditions, are gathered from medical records or Swedish national quality registers.

    Time frame: At baseline

  3. Cancer treatment

    Data regarding planned and received oncological and surgical cancer treatment (type, dose, treatment start and end date of treatment) and any treatment related side-effects are gathered from medical records and Swedish quality registers.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.

  4. Health care costs

    Data regarding outpatient visits, hospitalization and prescribed medication is gathered from Swedish national quality registers.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.

  5. Costs of intervention

    Data regarding cost of application use and any cost for physical activity is gathered from study records and patient reported by study specific questions.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.

  6. Sick leave

    Data regarding sick leave, i.e. total number of days being on sick leave gathered from the Swedish insurance fund (data on sick leave more than 14 days) and patient reported study specific questions (data on sick leave less than 14 days). Data will be gathered from 6 months prior baseline (study specific questions are administered at baseline and register data will be gathered at baseline but will include any data 6 months prior baseline).

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.

  7. Adherence

    Adherence to the intervention is assessed by Axivity accelometer and patient reported study specific questions.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.

  8. Green house gas emissions

    Green house emissions will be compared between the intervention and control group and estimated using a life cycle analysis of the technology used in the intervention, self-reported changes in climate behavior, and emissions from healthcare.

    Time frame: At baseline, 3-months, 6 months, 12 months and 24 months.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual medical information may not be shared with other researchers if the research questions are not within the scope of the current approved Swedish Ethical Review Board application (and any amendments) for this research. Only pseudonymous information may be shared after approval has been provided from the Swedish Ethical Review Board.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2029, 57 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 57 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Dec 5, 2024
StartActual
Mar 1, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2030
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
172→210
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Enrollment 172→210
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06719206
Lead sponsor
Mälardalen University
Collaborators
Region Västmanland, Uppsala University, Centrallasarettet Västerås, Uppsala University Hospital, Uppsala County Council, Sweden
Responsible party
Sponsor
First posted
Dec 5, 2024
Start date
Mar 1, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 1, 2026

Study contacts

Petra von Heideken Wågert, Professor
Contact
petra.heideken.wagert@mdu.se
+46 (0)21-10 3188
Anna Henriksson
Contact
anna.km.henriksson@uu.se
Petra von Heideken Wågert, Professor
principal investigator · Mälardalen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion